1-5 of 5
Shinji Kohsaka
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract C140: BI 1810631 is a novel EGFR wild-type sparing, HER2-selective small molecule inhibitor that efficiently blocks HER2 mutant-driven lung cancer

Ralph A. Neumüller, Birgit Wilding, Dirk Scharn, Anke Baum, Martin Augsten, Irene Waizenegger, Shinji Kohsaka, Valeria Santoro, Paolo Chetta, Lydia Woelflingseder, Johannes Popow, Daniel Gerlach, Peter Ettmayer, Thomas Gerstberger, Julian Fuchs, Matthias Treu, Stephan Zahn, Mark Pearson, Mark Petronczki, Darryl B. McConnell, Norbert Kraut, Flavio Solca
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): C140.
https://doi.org/10.1158/1535-7163.TARG-23-C140
Published: 01 December 2023
View articletitled, Abstract C140: BI 1810631 is a novel EGFR wild-type sparing, HER2-selective small molecule inhibitor that efficiently blocks HER2 mutant-driven lung cancer
Journal Articles

High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer

Sho Mizuno, Masachika Ikegami, Takafumi Koyama, Kuniko Sunami, Dai Ogata, Hidenori Kage, Mitsuru Yanagaki, Hiroshi Ikeuchi, Toshihide Ueno, Michihiro Tanikawa, Katsutoshi Oda, Yutaka Osuga, Hiroyuki Mano, Shinji Kohsaka
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (2): 227–239.
https://doi.org/10.1158/1535-7163.MCT-22-0302
Published: 01 February 2023
View articletitled, High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer
Open the PDF for High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer in another window
Includes: Supplementary data
Journal Articles

Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations

Hitomi Jo, Shigehiro Yagishita, Yoshiharu Hayashi, Shoraku Ryu, Mikiko Suzuki, Shinji Kohsaka, Toshihide Ueno, Yuji Matsumoto, Hidehito Horinouchi, Yuichiro Ohe, Shun-ichi Watanabe, Noriko Motoi, Yasushi Yatabe, Hiroyuki Mano, Kazuhisa Takahashi, Akinobu Hamada
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (2): 359–370.
https://doi.org/10.1158/1535-7163.MCT-21-0371
Published: 08 February 2022
View articletitled, Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations
Open the PDF for Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations in another window
Includes: Supplementary data
Journal Articles

Abstract A231: Let 7a regulates IL-6 expression in malignant mesothelioma.

Mishie A. Tanino, Shinji Kohsaka, Kazuhiro Yachi, Masumi Tsuda, Taichi Kimura, Hiroshi Nishihara, Shinya Tanaka
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A231.
https://doi.org/10.1158/1535-7163.TARG-13-A231
Published: 01 November 2013
View articletitled, Abstract A231: Let 7a regulates IL-6 expression in malignant mesothelioma.
Journal Articles

STAT3 Inhibition Overcomes Temozolomide Resistance in Glioblastoma by Downregulating MGMT Expression

Shinji Kohsaka, Lei Wang, Kazuhiro Yachi, Roshan Mahabir, Takuhito Narita, Tamio Itoh, Mishie Tanino, Taichi Kimura, Hiroshi Nishihara, Shinya Tanaka
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (6): 1289–1299.
https://doi.org/10.1158/1535-7163.MCT-11-0801
Published: 10 June 2012
View articletitled, STAT3 Inhibition Overcomes Temozolomide Resistance in Glioblastoma by Downregulating MGMT Expression
Open the PDF for STAT3 Inhibition Overcomes Temozolomide Resistance in Glioblastoma by Downregulating MGMT Expression in another window
Includes: Supplementary data